AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

MESOBLAST LTD

2.355

-0.005-0.21%

Volume:792.63K

Turnover:1.87M

Market Cap:3.05B

PE:-22.93

High:2.395

Open:2.390

Low:2.330

Close:2.360

52wk High:3.310

52wk Low:1.880

Shares:1.30B

Float Shares:786.49M

Volume Ratio:0.46

T/O Rate:0.10%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.103

EPS(LYR):-0.118

ROE:-18.22%

ROA:-6.16%

PB:3.81

PE(LYR):-19.95

Loading ...

Overview Company News Filings

Cynata Therapeutics' Drug Candidate's Potential Reinforced by Mesoblast Results, Says Euroz Hartleys

MT Newswires Live

Monero price flips daily structure bullish, $473 target emerges

Mesoblast (ASX:MSB) Valuation After Earnings Update And New Ryoncil Revenue Guidance

Simply Wall St.

Stock Track | Mesoblast Plummets 8.93% Intraday After Jefferies Cuts Price Target

Organic Growth in Australia's Healthcare Services Likely Due to Increased Availability of Bulk-Billing General Practitioners, Jefferies Says

MT Newswires Live

Mesoblast H1 2026 Loss Of US$94.4 Million Tests Bullish Profitability Narratives

Simply Wall St.

Why Mesoblast (ASX:MSB) Is Down 7.1% After Issuing First Detailed Ryoncil Revenue Guidance

Simply Wall St.

Mesoblast Posts HY Total Revenues $51.3 Million

ASX Biggest Losers

MT Newswires Live

BRIEF-Mesoblast Sees Full-Year Fiscal 2026 Ryoncil Net Revenue To Range Between $110 Million And $120 Million

Mesoblast posts H1 FY2026 revenue of USD 51.3 million, 16.0x

Ryoncil® Profits Underpinning Substantial Growth Pipeline

THOMSON REUTERS

Stock Track | Mesoblast Ltd Plummets 5.17% Intraday on Half-Year Loss and Revenue Guidance

Press Release: Ryoncil(R) Profits Underpinning Substantial Growth Pipeline

Stock Track | Mesoblast Soars 5.79% Intraday on Positive Ryoncil Revenue Guidance

Mesoblast Ltd - Sees Full-Year Fiscal 2026 Ryoncil Net Revenue to Range Between US$110 Million and US$120 Million

THOMSON REUTERS

Mesoblast Ltd - Hy Total Revenues $51.3 Mln

THOMSON REUTERS

Mesoblast Ltd expected to post a loss of 7 cents a share - Earnings Preview

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/MSB.AU/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"MSB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","market":"AU","secType":"STK","nameCN":"MESOBLAST LTD","latestPrice":2.355,"timestamp":1787540385170,"preClose":2.36,"halted":0,"volume":792630,"delay":0,"changeRate":-0.002118644067796565,"nameEN":"MESOBLAST LTD","floatShares":786490638,"shares":1296862776,"eps":-0.10271582397395847,"marketStatus":"Trading","change":-0.005,"latestTime":"08-24 13:00:11 AEST","open":2.39,"high":2.395,"low":2.33,"amount":1873149,"amplitude":0.027542,"askPrice":2.36,"askSize":2688,"bidPrice":2.35,"bidSize":44513,"shortable":3,"etf":0,"ttmEps":-0.10271582397395847,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787551200000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":2.36,"openAndCloseTimeList":[[1787529600000,1787551200000]],"volumeRatio":0.464753,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"MSB.AU","preClose":2.36,"auctionPrice":2.39,"auctionVolume":3958,"auctionTime":1787529540683,"referenceTime":1787308204093,"auction":1,"marketStatus":"盘前竞价","timestamp":1787529540683}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","floatShares":786490638,"roa":"-6.16%","roe":"-18.22%","lyrEps":-0.118048,"volumeRatio":0.464753,"shares":1296862776,"dividePrice":0,"high":2.395,"amplitude":0.027542,"preClose":2.36,"low":2.33,"week52Low":1.88,"pbRate":"3.81","psRate":"33.46","week52High":3.31,"institutionHeld":0,"latestPrice":2.355,"committee":0.886104,"eps":-0.10271582397395847,"divideRate":0,"volume":792630,"delay":0,"ttmEps":-0.10271582397395847,"open":2.39,"prevYearClose":2.72,"prevWeekClose":2.36,"prevMonthClose":2.05,"prevQuarterClose":1.955,"fiveDayClose":2.45,"twentyDayClose":2.14,"sixtyDayClose":2.14,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MSB.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-26","symbol":"MSB.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MSB.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MSB.AU\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2618617137","title":"Cynata Therapeutics' Drug Candidate's Potential Reinforced by Mesoblast Results, Says Euroz Hartleys","url":"https://stock-news.laohu8.com/highlight/detail?id=2618617137","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618617137?lang=en_us&edition=fundamental","pubTime":"2026-03-09 14:37","pubTimestamp":1773038279,"startTime":"0","endTime":"0","summary":"Cynata Therapeutics'  acute graft-versus-host disease  drug candidate, CYP-001's potential has been reinforced by Mesoblast's  fiscal first half results, said Euroz Hartleys in a Monday note.Mesoblast's results showed its product, Ryoncil, which is a mesenchymal stem cell therapy approved by the US FDA for the treatment of paediatric , generated $49 million in net sales during the period and guided towards full-year net sales of $110 million to 120 million.CYP-001 is currently in a phase 2 trial, with topline results expected in June, the note added.The research firm believes that CYP-001 could attract significant commercial interest if it successfully replicates its Phase 1 results, which showed about 86% overall response rate at Day 28 versus about 62% for standard of care.Euroz Hartleys has maintained a speculative buy rating on Cynata Therapeutics with a price target of AU$0.90.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","MESO","MSB.AU","BK7067","BK4539","BK7501","CYP.AU","LENZ","BK7508","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617578255","title":"Monero price flips daily structure bullish, $473 target emerges","url":"https://stock-news.laohu8.com/highlight/detail?id=2617578255","media":"cryptonews","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617578255?lang=en_us&edition=fundamental","pubTime":"2026-03-06 03:20","pubTimestamp":1772738431,"startTime":"0","endTime":"0","summary":"Monero price has confirmed a bullish market structure shift on the daily timeframe after reclaiming key support. If the $357 level continues to hold, the next major upside target sits at the $473 resistance.Bullish structure confirmed:Monero printed a higher low followed by a new higher high on the daily chart.$357 flipped to support:Former resistance now acting as key support for continuation.$473 target:Next major high-timeframe resistance if bullish momentum holds.Monero  price is beginning to show renewed bullish momentum after a decisive structural shift on the daily chart. The recent price action suggests that buyers have regained control of the market following a confirmed break in market structure.Such structural confirmations often precede strong directional moves as market participants reposition in line with the new trend. In the broader market narrative, several leading cryptocurrencies attracting trader attention include BCH, XMR, HYPE, and BlockDAG, as investors continue ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"crypto_news_highlight","url":"https://crypto.news/monero-price-flips-daily-structure-473-target-emerges/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://crypto.news/monero-price-flips-daily-structure-473-target-emerges/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"crypto_news_highlight","symbols":["BK7501","BK7508","BK7067","MSB","BK4006","MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616313728","title":"Mesoblast (ASX:MSB) Valuation After Earnings Update And New Ryoncil Revenue Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2616313728","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616313728?lang=en_us&edition=fundamental","pubTime":"2026-03-03 12:50","pubTimestamp":1772513408,"startTime":"0","endTime":"0","summary":"Why Mesoblast’s latest guidance matters for shareholders\nMesoblast (ASX:MSB) has just paired a detailed half year earnings update with new revenue guidance for its key product Ryoncil, giving investors fresh numbers on both recent performance and management expectations.\nThe company reported half year revenue of US$51.34 million and a net loss of US$40.16 million, and now forecasts full year 2026 Ryoncil net revenue between US$110 million and US$120 million.\nSee our latest analysis for...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-after-earnings-update-and-new-ryo","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-after-earnings-update-and-new-ryo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MSB.AU","MSB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124310967","title":"Stock Track | Mesoblast Plummets 8.93% Intraday After Jefferies Cuts Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=1124310967","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124310967?lang=en_us&edition=fundamental","pubTime":"2026-03-02 12:30","pubTimestamp":1772425825,"startTime":"0","endTime":"0","summary":"Mesoblast Ltd's stock plummeted 8.93% during Monday's intraday trading session following a downward revision of its price target by investment firm Jefferies.The stock decline came after Jefferies...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616804550","title":"Organic Growth in Australia's Healthcare Services Likely Due to Increased Availability of Bulk-Billing General Practitioners, Jefferies Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2616804550","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616804550?lang=en_us&edition=fundamental","pubTime":"2026-03-02 12:27","pubTimestamp":1772425659,"startTime":"0","endTime":"0","summary":"An organic growth in Australian healthcare services is likely due to improving availability of bulk-billing general practitioners, offset by ongoing wage pressures, Jefferies said in a Monday report.I","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SHL.AU","BK7089","IMM.AU","FPH.AU","XAO.AU","BK7103","IDX.AU","XBI","XKO.AU","HLS.AU","COH.AU","CSL.AU","BK7126","ANN.AU","MVF.AU","BK4585","LABU","BK4588","BK7007","BK7501","BK7067","CU6.AU","NHF.AU","XLV","BK7511","BK7096","BK7508","BK7124","BK7509","BK4581","TLX.AU","BK7113","MSB.AU","CUV.AU","RHC.AU","HCAR","NEU.AU","XJO.AU","REG.AU","MPL.AU","SIG.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616227846","title":"Mesoblast H1 2026 Loss Of US$94.4 Million Tests Bullish Profitability Narratives","url":"https://stock-news.laohu8.com/highlight/detail?id=2616227846","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616227846?lang=en_us&edition=fundamental","pubTime":"2026-03-01 01:28","pubTimestamp":1772299685,"startTime":"0","endTime":"0","summary":"Mesoblast (ASX:MSB) opened H1 2026 with revenue of US$14.0 million and a basic EPS loss of US$0.04, while trailing 12 month figures in the dataset show revenue of US$65.4 million and a net loss of US$94.4 million. The company has seen revenue move from US$2.5 million in H2 2024 to US$3.2 million in H1 2025 and then to US$14.0 million in H2 2025, with basic EPS losses in those periods ranging between US$0.04 and US$0.05. The latest results therefore keep the focus on how quickly revenue can...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-h1-2026-loss-of-us944-million-tests-bullish-profit","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-h1-2026-loss-of-us944-million-tests-bullish-profit","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7501","BK7067","BLSG","BLSX","MSB.AU","BK7508","BK4112","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614868789","title":"Why Mesoblast (ASX:MSB) Is Down 7.1% After Issuing First Detailed Ryoncil Revenue Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2614868789","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614868789?lang=en_us&edition=fundamental","pubTime":"2026-02-27 23:46","pubTimestamp":1772207166,"startTime":"0","endTime":"0","summary":"Mesoblast Limited recently reported half-year 2025 results, with revenue rising to US$51.34 million and net loss and loss per share both narrowing, and subsequently issued fiscal 2026 guidance calling for US$110 million to US$120 million in Ryoncil net revenue.\nThis combination of sharply higher reported revenue and the first detailed full-year outlook for Ryoncil offers investors a clearer view of Mesoblast’s early commercial trajectory and cost profile.\nWe’ll now examine how Mesoblast’s...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/why-mesoblast-asxmsb-is-down-71-after-issuing-first-detailed","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/why-mesoblast-asxmsb-is-down-71-after-issuing-first-detailed","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MSB.AU","MSB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614001990","title":"Mesoblast Posts HY Total Revenues $51.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614001990","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614001990?lang=en_us&edition=fundamental","pubTime":"2026-02-27 10:13","pubTimestamp":1772158413,"startTime":"0","endTime":"0","summary":"Feb 27 (Reuters) - Mesoblast Ltd ::*HY TOTAL REVENUES $51.3 MILLION*HY LOSS ATTRIBUTABLE $40.2 MILLION*Further company coverage: MSB.AX* ((Reuters.Briefs@thomsonreuters.com;))  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 27-FEB-202602:03:10 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nRSD2kTnKS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSB.AU","BK7501","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614001368","title":"ASX Biggest Losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2614001368","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614001368?lang=en_us&edition=fundamental","pubTime":"2026-02-27 10:02","pubTimestamp":1772157763,"startTime":"0","endTime":"0","summary":"Here are the 10 ASX-listed companies with the biggest losses on Friday.Coles Group : -9%, AU$20.12Liontown : -7%, AU$1.6850Harvey Norman Holdings : -7%, AU$5.86Worley : -6%, AU$10.95Mesoblast : -6%, AU$2.27IGO : -4%, AU$8.53NEXTDC : -4%, AU$13.72TPG Telecom : -4%, AU$3.89Perenti : -3%, AU$2.3550Genesis Energy  : -3%, AU$1.96","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LTR.AU","BK7095","BK7043","BK7506","PRN.AU","BK7055","WOR.AU","TPG.AU","BK7108","MSB.AU","IGO.AU","BK7503","BK7041","HVN.AU","BK7504","BK7040","BK7501","BK7507","COL.AU","BK7006","BK7067","BK7153","BK7082","GNE.AU","BK7508","BK7042","NXT.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614009566","title":"BRIEF-Mesoblast Sees Full-Year Fiscal 2026 Ryoncil Net Revenue To Range Between $110 Million And $120 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614009566","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614009566?lang=en_us&edition=fundamental","pubTime":"2026-02-27 09:41","pubTimestamp":1772156490,"startTime":"0","endTime":"0","summary":"BRIEF-Mesoblast Sees Full-Year Fiscal 2026 Ryoncil Net Revenue To Range Between $110 Million And $120 MillionFeb 27  - Mesoblast Ltd MSB.AX:SEES FULL-YEAR FISCAL 2026  RYONCIL NET REVENUE TO RANGE BETWEEN  US$110 MILLION AND US$120 MILLIONFurther company coverage: MSB.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nFWN3ZM249:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","BK7501","MSB.AU","BK4139","MESO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614005300","title":"Mesoblast posts H1 FY2026 revenue of USD 51.3 million, 16.0x","url":"https://stock-news.laohu8.com/highlight/detail?id=2614005300","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614005300?lang=en_us&edition=fundamental","pubTime":"2026-02-27 08:43","pubTimestamp":1772153001,"startTime":"0","endTime":"0","summary":"Mesoblast posts H1 FY2026 revenue of USD 51.3 million, 16.0x               Mesoblast (MESO) reported H1 FY2026 total revenue of USD 51.3 million, up from USD 3.2 million, driven by the U.S. commercial","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nNDL7Jkf4x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","SG9999014013.SGD","LU0314104364.USD","LU2210150020.SGD","BK4588","SG9999014039.USD","BK4112","IE00BKPKM429.USD","MSB.AU","SG9999014005.SGD","BK7508","BK7067","LU2095319765.USD","BK4585","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","BK7501","LU2210149790.SGD","IE00B64PRP62.GBP","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614053220","title":"Ryoncil® Profits Underpinning Substantial Growth Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2614053220","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614053220?lang=en_us&edition=fundamental","pubTime":"2026-02-27 08:42","pubTimestamp":1772152974,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nTUA6XZHMM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MSB.AU","BK7501","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107120223","title":"Stock Track | Mesoblast Ltd Plummets 5.17% Intraday on Half-Year Loss and Revenue Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=1107120223","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107120223?lang=en_us&edition=fundamental","pubTime":"2026-02-27 08:42","pubTimestamp":1772152954,"startTime":"0","endTime":"0","summary":"Mesoblast Ltd's stock price plummeted 5.17% during intraday trading on Friday, following the release of the company's financial results and guidance.The biotech company reported a half-year loss...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614005533","title":"Press Release: Ryoncil(R) Profits Underpinning Substantial Growth Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2614005533","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614005533?lang=en_us&edition=fundamental","pubTime":"2026-02-27 08:42","pubTimestamp":1772152920,"startTime":"0","endTime":"0","summary":"NEW YORK, Feb. 26, 2026  -- Mesoblast Limited , global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended December 31, 2025 .Performance driven by successful commercial launch of Ryoncil. -- Total revenue of US$51.3 million ,2 up from US$3.2. generated gross sales of US$57.0 million and revenue of US$48.7 million. -- Ryoncil gross profit, excluding amortization, was US$44.2 million. versus nil in the prior year period. Direct selling costs were US$7.7. -- The strong operating performance in the period allowed us to invest in. R&D, including to support the Phase 3 trial on the blockbuster chronic. -- Reported net loss of US$40.2 million compared to US$47.9 million, an. improvement of US$7.8 million. Excluding a US$23.0 million inventory. -- Net operating cash spend of US$30.3 million. Mesoblast expects to see. -- Period-end cash balance of US$130.0 million. Mesoblast entered into a. US$125.0 ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","R","LU2500361329.USD","LU1003077747.HKD","BK4022","LU2637428348.USD","BK7067","LU0949170772.SGD","LU2346227817.USD","LU0661504455.SGD","CMS","BK4232","BK4150","BK7508","LU0553294199.USD","BK4139","MSC","BK4575","LU1894683264.USD","BK4208","LU0545039389.USD","LU0738911758.USD","BK7501","MSB.AU","MESO","LU1894683348.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128522861","title":"Stock Track | Mesoblast Soars 5.79% Intraday on Positive Ryoncil Revenue Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=1128522861","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128522861?lang=en_us&edition=fundamental","pubTime":"2026-02-27 07:03","pubTimestamp":1772146980,"startTime":"0","endTime":"0","summary":"Mesoblast Ltd's stock surged 5.79% during intraday trading on Friday, marking a significant upward movement for the biotech company.The sharp rise appears to be driven by the company's optimistic...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614717700","title":"Mesoblast Ltd - Sees Full-Year Fiscal 2026  Ryoncil Net Revenue to Range Between  US$110 Million and US$120 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614717700","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614717700?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:50","pubTimestamp":1772142640,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nFWN3ZM249:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","BK7501","MSB.AU","BK4139","MESO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614071169","title":"Mesoblast Ltd - Hy Total Revenues $51.3 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2614071169","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614071169?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:44","pubTimestamp":1772142247,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nFWN3ZM297:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MSB.AU","BK7501","MESO","BK7067","BK7508","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614856530","title":"Mesoblast Ltd  expected to post a loss of 7 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2614856530","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614856530?lang=en_us&edition=fundamental","pubTime":"2026-02-25 19:10","pubTimestamp":1772017813,"startTime":"0","endTime":"0","summary":"Mesoblast Ltd  expected to post a loss of7cents a share - Earnings Preview Mesoblast Ltd MESO.OQ, MESO.O is expected to  report resultson February 27 for the period ending September 30 2025The Melbour","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nL8N3ZL106:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MSB.AU","MESO","BK7067","BK7508","BK7501"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":9,"totalSize":178,"code":"91000000","status":"200"}]}}